Keytrida plus Lenvima improved survival and duration of response in patients with advanced hepatocellular carcinoma. Adding Keytruda (pembrolizumab) to Lenvima (lenvatinib) led to better duration of ...

Among the 27 responding patients, 81% had a duration of response (DOR) of six months or longer, and 37% had a DOR of 12 months or longer. In June 2020, KEYTRUDA was granted its first indication in ...

Trodelvy plus Keytruda may maintain QOL and delay physical decline in PD-L1-positive mTNBC patients. The combination therapy showed improved progression-free survival and reduced symptom burden ...

After AstraZeneca’s Imfinzi last year claimed new territory in the biliary tract cancer space, Merck’s Keytruda has hit the scene with an FDA nod to match its rival. The approval in locally advanced ...

Results showed an overall response rate of 50%, with 17% of patients achieving complete response and 33% having partial response. The Food and Drug Administration (FDA) has expanded the approval of ...

Merck & Co.’s Keytruda has added a third bladder cancer use to its label. With an FDA nod Wednesday, Keytruda has become the first PD-1/L1 inhibitor approved to treat patients with superficial but ...

The approval was based on data from cohorts D and K of the phase 2 KEYNOTE-158 trial, which included patients with multiple types of advanced solid tumors. The Food and Drug Administration (FDA) has ...

Imfinzi (durvalumab) and Keytruda (pembrolizumab) are prescription drugs used to treat various forms of cancer. Both drugs are administered as intravenous (IV) infusion into a vein. Your dosage for ...

Doctors monitor Keytruda’s effectiveness using imaging tests like CT or MRI scans to check tumor size. (Sometimes tumors may appear larger initially due to a phenomenon called pseudoprogression.) ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...